Impact

Research and Innovation with Global Influence

With our vision of patient-driven care for all Canadians, along with ground-breaking CANet-funded research, we continue to assemble innovative digital health technologies.

Outside of VIRTUES, our patient-centred virtual care platform, several of our successful research programs have a global impact. 

Network Stats

(2015 – 2021)

  • 886 CANet-funded publications
  • 7 commercialized technologies
  • 10 patents filed, 6 patents issued
  • 3 trademarks
  • 3 start-up companies created

Research

AED Drone Delivery

90th percentile Improvement in AED arrival

Canada’s first AED delivered by drone.

AED Drone Delivery

  • Successfully conducted the first-ever reported test flights of drone-delivered AEDs in Canada in two rural locations in Ontario (Town of Caledon and County of Renfrew) simulating mock 9-1-1 responses.
  • Successfully demonstrated the ability to integrate a dispatcher-assisted CPR application through a facetime app on the drone-delivered AED
  • Significantly reduced the time to AED arrival at the scene of a cardiac arrest from 20 minutes to 10.6 minutes in rural regions. The chances of surviving a cardiac arrest decrease by 7 to 10 % for every minute over 10 minutes.

EARLY-AF

Largest clinical trial of its kind

Significantly lower rate of atrial fibrillation recurrence with catheter cryoballoon ablation.

EARLY-AF

  • It was found that there was a significantly lower rate of atrial fibrillation recurrence with catheter cryoballoon ablation than with antiarrhythmic drug therapy
  • One of the first programs funded by CANet, this research has recently been published in the New England Journal of Medicine with numerous presentations at national/international conferences as a keynote lecture.
  • Since the inception and conduct of this study, the Canadian manufactured cryo-balloon ablation procedure has been adopted widely in Canada and internationally. There has been an incremental employment of over 200 highly skilled and professional individuals in CryoCath facility, Pointe-Claire, Quebec.
  • This study also incorporates another Canadian invention, RF transseptal technology (Baylis Medical). This study will showcase this technology to the world.

C-SCAN 

Mandatory AED registry in Ontario

Provincial AED registry, Bill 141 Defibrillator Registration, and Public Access Act, 2020. 

C-SCAN

  • C-SCAN has linked multisource datasets including EMS, coroner, and administrative to accurately track all SCAs across Canada involving 8 Provinces and 2 Territories representing 31 EMS agencies. This dataset represents over 82,000 enrolled patients.
  • This is the first-ever pan-Canadian measure of the number and distribution of SCA patients arriving to the hospital and for the first time allows interprovincial and inter-region comparisons of incidence and outcomes.
  • Successfully advocated for a mandatory AED registry in Ontario and helped draft legislation to create a mandatory Provincial AED registry, Bill 141 Defibrillator Registration, and Public Access Act, 2020. This legislation received royal assent in June 2020.
  • Hosted an educational event attended by over 30 MPPs and numerous staffers at the Ontario Legislature to teach MPPs about how to perform CPR and use an AED and raise awareness.

Canadian Syncope Risk Score (CSRS)

Canada-Wide Implementation

Optimizes the management of syncope patients.

Canadian Syncope Risk Score (CSRS)

  • The CSRS tool enhances the identification of low-risk syncope patients for early discharge and reduces unnecessary hospital admissions and healthcare costs
  • The CSRS has being implemented in 16 clinical practice sites across 4 provinces
  • The CSRS tool can be accessed on the MDCalc website and app that is currently used in 196 countries with 1 million monthly users. It is also accessible on the Calculate by QxMD app, a similar platform that has over 400 medical decision support tools encompassing all specialties

AF Treatment in the ED

Patients with acute atrial fibrillation (AAF)

ED management to avoid hospitalizations.

AF Treatment in the ED

  • Successfully implemented the developed AAF guideline into 11 large Canadian EDs across 5 Provinces in over 718 patient visits. This AAF guideline is now being shared across the Canadian emergency medicine community to be used as a bedside tool for physicians.
  • The AAF guidelines have reduced the patient length of stay in the ED by 21%.
  • Pilot implementation of these guidelines has reduced hospitalization from 40% to 3.5%.
  • These practice guidelines have been adopted into the Canadian ED Best Practice Guidelines.

REFINE-ICD

Preventing SCD in at-risk Patients

Identifying patients at risk of SCD and determining if an implantable defibrillator can prevent their SCD.

REFINE-ICD

  • Over 500 patients have been enrolled across 30 clinical sites throughout Canada (71% of the enrollment target).
  • Results to date have demonstrated that individuals with BOTH abnormal TWA and impaired HRT have a 9-fold higher death rate than do those patients without these abnormalities.
  • The results of this research will have a major impact on the management of post-MI patients. If the implantable defibrillator is shown to prevent SCD in these patients, their overall mortality will be reduced; these patients contribute to 7% of the incidence of SCD, optimization of treatments will reduce SCD by 15%.

Commercialization

Aufero Medical Technologies

Catheter Contact-Force Controller for Cardiac Ablation Therapy

1 patent issued

Aufero Medical has developed a Catheter Contact-Force Controller (CFC) device that can be used in conjunction with standard catheters to instantaneously adjust the catheter position and control contact force. This technology will greatly improve the ablation procedure for atrial fibrillation and will reduce AF recurrence after ablation. As a direct result of CANet investment, Aufero Medical has received more than $500,000 in CIHR and investment funding.

42 Health Inc.

A Transcutaneous Physiologic Sensor for Home and Clinical Use

2 patents filed

2 Health Inc. (CANet supported start-up) is developing a small wearable transcutaneous blood pressure (BP) monitor device that weighs a fraction of an ounce. The device measures the BP of every heartbeat, measures blood oxygen levels, can detect when one falls, stores episodes of arrhythmias, and does this wirelessly. The digital data is transmitted to other devices, such as a smartphone. 42 Health has filed 2 patents and is currently being incubated at the University of Calgary.

Conavi Medical

Catheter-based Imaging Tools for Characterization of Myocardial Ablation Lesions

8 patents issued

By coupling ablations with state-of-the-art imaging methods, such as high-resolution ultrasound, physicians are able to visualize the site of the catheter ablation in the heart in real-time to improve the outcomes of the procedure by more effectively destroying the abnormal tissue that is causing the heart rhythm problem. The prototype is ready for clinical testing and has resulted in 8 patents.

Arvarda Therapeutics Inc.

An Accurate Simple Blood Test for Arrhythmogenic Cardiomyopathy

4 patents filed

Arvarda Therapeutics Inc. has identified a novel biomarker that has led to the creation of a simple, accurate blood test for ARVC (arrhythmogenic right ventricular cardiomyopathy). ARVC is an inherited heart rhythm disorder that is responsible for 11% of sudden death in adults, 22% in athletes, and 25% in children and is difficult to diagnose with current clinical or genetic testing. As a direct result of CANet investment, more than $1.6M in CIHR and internal institutional funding has been received.